Eligible patients were aged at least 18 years with histologically confirmed , chemotherapy-naive , stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression ( Response Evaluation Criteria in Solid Tumors version 1.1 ) .